GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer

$326,214
Adam Joel Bass · Columbia University Health Sciences · P01 · FY2019 · CA

Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma

$326,033
Robert Wi Chen · Beckman Research Institute/City Of Hope · P50 · FY2019 · CA

Human Biosamples Core

$326,023
Elizabeth W Karlson · Brigham And Women'S Hospital · P30 · FY2025 · AR

Mechanisms of Progression in Oncogene-Incuded Prostate Cancer

$325,941
Timothy C Thompson · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · CA

Immunotherapeutic targeting of MIF-dependent chaperone activity

$325,842
Robert A. Mitchell · University Of Louisville · R01 · FY2024 · CA

Validating the protein binding domain of replication protein A as a cancer target

$325,775
Stephen W. Fesik · Vanderbilt University · R01 · FY2016 · CA

Validating the protein binding domain of replication protein A as a cancer target

$325,775
Stephen W. Fesik · Vanderbilt University · R01 · FY2015 · CA

14 3 3 Implications in Topoisomerase II Pharmacology

$325,736
Research Triangle Institute · R01 · FY2003 · CA

14 3 3 Implications in Topoisomerase II Pharmacology

$325,697
Research Triangle Institute · R01 · FY2002 · CA

Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer

$325,680
Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation

$325,547
Douglas G McNeel · University Of Wisconsin-Madison · P01 · FY2021 · CA

SPINK7 in allergic inflammation

$325,412
Marc E. Rothenberg · Cincinnati Childrens Hosp Med Ctr · U19 · FY2019 · AI

B55 alpha deficiency as a therapeutic target in cancer

$325,395
Junran Zhang · Ohio State University · R01 · FY2024 · CA

Function and Regulation of Pin2/TRF1 and PinX1

$325,370
Beth Israel Deaconess Medical Center · R01 · FY2005 · GM

p53 and checkpoint pathways in cancer cell repliction

$325,345
Anindya Dutta · University Of Virginia · R01 · FY2008 · CA

p53 and checkpoint pathways in cancer cell repliction

$325,345
Anindya Dutta · University Of Virginia · R01 · FY2007 · CA

Cdk-2 Independent role of cyclin E in Cell survival

$325,302
Alexandru Almasan Almasan · Cleveland Clinic Lerner Com-Cwru · R01 · FY2009 · CA

Cdk-2 Independent role of cyclin E in Cell survival

$325,302
Alexandru Almasan Almasan · Cleveland Clinic Lerner Com-Cwru · R01 · FY2010 · CA

Validating the protein binding domain of replication protein A as a cancer target

$325,256
Stephen W. Fesik · Vanderbilt University · R01 · FY2014 · CA

Fu - Proj 3

$325,152
Feng Fu · Dartmouth College · P20 · FY2021 · GM

Targeting macrophages to sensitize myeloma to immune checkpoint blockade

$325,059
Qing Yi · Methodist Hospital Research Institute · R01 · FY2019 · CA

The Pancreatic Cancer Microenvironment

$325,020
Rui Kang · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · CA

Novel chemistry to improve the biostability of organo-astatine bonds in alpha-emitting radiopharmaceutical therapeutics

$325,000
Hsiaoju Sharon Lee · University Of Pennsylvania · R21 · FY2022 · EB

Replication Stress and DNA Damage Response Drives ESR1 Mutant Metastasis

$324,901
Suzanne A Fuqua · Baylor College Of Medicine · R01 · FY2024 · CA

Targeting EphB4-ephrinB2 to decrease immunosuppression in HNSCC

$324,855
Sana D Karam · University Of Colorado Denver · P50 · FY2022 · CA